CSL shares down 5% af­ter post-heart at­tack drug dis­ap­points in late-stage test

CSL’s cho­les­terol ef­flux en­hancer failed to pre­vent re­peat car­diac events in a Phase III study that re­cruit­ed pa­tients who had a re­cent my­ocar­dial in­farc­tion, prompt­ing a drop in the com­pa­ny’s share price.

The Phase III AEGIS-II tri­al test­ed the drug, CSL112, against place­bo in more than 18,200 pa­tients in the 90-day high-risk pe­ri­od af­ter a heart at­tack. The treat­ment missed the pri­ma­ry end­point of re­duc­ing ma­jor ad­verse car­dio­vas­cu­lar events (MACE) at 90 days. There were no ma­jor safe­ty or tol­er­a­bil­i­ty con­cerns, CSL said in a com­pa­ny re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.